BPC-157 & TB-500 BPC-157 & TB-500 PRODUCT IMAGE
HPLC VERIFIED CoA SUPPLIED ≥99% PURITY
★★★★★ Reviews
— Recovery

BPC-157 & TB-500 Dual-Action Angiogenic & Tissue Research Blend

For in vitro research use only. BPC-157 & TB-500 is not for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.

A single vial containing 10mg of BPC-157 and 10mg of TB-500 — two of the most widely studied tissue-repair peptides in preclinical research. Combining them in one vial means researchers only need to reconstitute (dissolve and prepare) the compound once to work with both together.

CAS Number
137525-51-0 / 77591-33-4
Molecular Formula
BPC-157 (C₆₂H₉₈N₁₆O₂₂) + TB-500 fragment
HPLC Purity
≥99% (batch-verified)
Form
Lyophilised powder
Storage
2–8°C, desiccated, protected from light
Classification
Research reagent — in vitro use only
≥99%
HPLC purity
3rd-Party Tested
Independent lab
CoA Every Order
Batch-specific
Tracked 24
Royal Mail UK
Pay by Bank
No card stored

Research overview

The BPC-157 & TB-500 combination vial from Velox Peptides contains both peptides co-lyophilised in a single sterile vial — a convenient format for research protocols that incorporate both compounds simultaneously. BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic pentadecapeptide studied in the context of angiogenesis, tendon and ligament repair, gastrointestinal mucosal protection, and VEGF signalling. TB-500 is a synthetic peptide fragment of Thymosin Beta-4 (Tβ4), studied for its role in actin-mediated cell motility, tissue repair, and new blood vessel formation. Together, they represent two of the most widely studied repair-associated peptides in preclinical research.

The rationale for combining BPC-157 and TB-500 in preclinical research derives from their complementary mechanisms. BPC-157’s effects have been primarily studied through its interaction with growth hormone receptor expression and vascular endothelial growth factor (VEGF) pathways — promoting angiogenic and tissue growth signals in rodent wound and tendon models. TB-500’s core mechanism centres on the LKKTET actin-binding sequence of Thymosin Beta-4, which sequesters G-actin monomers and promotes the directed cell motility necessary for wound closure. Studies combining both peptides in rodent models have examined whether their distinct mechanistic profiles produce additive or synergistic effects on tissue repair endpoints.

The combination vial contains each compound at its individual research-grade specification: BPC-157 at ≥99.4% HPLC purity and TB-500 at ≥99% HPLC purity, co-lyophilised in defined proportions. Batch documentation is available on request. Researchers requiring independent dosing of each compound should order BPC-157 and TB-500 individually — both are available separately in the Healing & Repair category. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.

Compound specifications

Common nameBPC-157 & TB-500
Full nameDual-Action Angiogenic & Tissue Research Blend
CAS number137525-51-0 / 77591-33-4
Molecular formulaBPC-157 (C₆₂H₉₈N₁₆O₂₂) + TB-500 fragment
Molecular weight1419.5 + 4963.4 g/mol
SequenceGEPPPGKPADDAGLV (BPC-157) + Ac-SD...Ac-SDKPDMAEIEKFDKS-fragment (TB-500)
HPLC purity≥99% (batch-verified)
AppearanceWhite to off-white lyophilised powder
SolubilityBacteriostatic water, sterile saline
Storage (lyophilised)2–8°C, protected from light
Storage (reconstituted)2–8°C, up to 28 days
Supplied as20mg (10mg BPC-157 + 10mg TB-500)

Batch testing and certificate of analysis

Every batch of BPC-157 & TB-500 is third-party HPLC-tested prior to dispatch. Batch documentation is available on request.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact support@veloxpeps.com.

Frequently Asked Research-Use Questions

What is in the BPC-157 & TB-500 vial?
Each vial contains 10mg of BPC-157 (Body Protection Compound-157) and 10mg of TB-500 (synthetic thymosin beta-4 fragment), co-lyophilised in a single sterile vial — 20mg total peptide content.
What purity is the BPC-157 & TB-500?
The BPC-157 & TB-500 is supplied at ≥99% HPLC-verified purity for both components. Batch documentation is available on request.
How is the BPC-157 & TB-500 reconstituted for research use?
The mix is supplied as a co-lyophilised powder in a single sterile vial. For in vitro research use, reconstitution is performed with bacteriostatic water. See the reconstitution calculator for volume calculations based on your required concentration.
What is the difference between the BPC-157 & TB-500 and the BPC-157 + TB-500 Bundle?
The Mix supplies both compounds co-lyophilised together in a single 20mg vial — one reconstitution step for both. The Bundle supplies BPC-157 and TB-500 as two separate individual vials (10mg each), allowing independent dosing and reconstitution of each compound. The Mix suits protocols where both compounds are always used together; the Bundle offers greater flexibility.
Is BPC-157 & TB-500 legal to buy in the UK?
Yes. BPC-157 & TB-500 is lawful to purchase in the United Kingdom strictly for legitimate in vitro scientific research purposes. It is not a controlled substance under UK law and is not subject to prescription requirements when purchased for research use. Velox Peptides supplies BPC-157 & TB-500 solely as a research reagent to qualified researchers. Buyers are responsible for ensuring all use complies with applicable law and with Velox Peptides’ Research Use Policy.
How does the combination vial differ from ordering BPC-157 and TB-500 separately?
The combination vial contains both BPC-157 and TB-500 co-lyophilised together in a single sterile vial at fixed proportions, requiring only one reconstitution step. This is convenient for research protocols where both compounds are consistently used together. Ordering the compounds separately allows independent dosing of each peptide — useful if your research design requires different concentrations or separate dosing schedules for each compound. Both options are available from Velox Peptides. The individual compound pages are BPC-157 and TB-500.
How quickly is my order dispatched and delivered?
Orders placed before 2pm on a working day are dispatched the same day via Royal Mail Tracked 24, typically arriving in 1–2 working days, with tracking emailed on dispatch. UK shipping is free over £80, and EU shipping is available.
How do I pay, and is it secure?
We accept Pay by Bank — an instant, secure open-banking payment via Fena, where you authorise the payment in your own banking app and no card details are stored on our site. Manual UK bank transfer is available as a fallback. Orders are dispatched within 24 hours of cleared payment.
Does my order include a certificate of analysis?
Yes. Every order includes a batch-specific Certificate of Analysis documenting third-party HPLC purity and mass-spectrometry identity confirmation, emailed with your order confirmation. Previous batch CoAs are archived in our CoA library.

For in vitro research use only. BPC-157 & TB-500 is supplied solely as a research reagent for qualified professionals conducting in vitro or animal-model studies. It is not a medicinal product within the meaning of the Human Medicines Regulations 2012. It has not been evaluated by the MHRA or FDA. It is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale.

Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.